Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of UCB5857. Part 1 of the study explores single doses
of the drug. Part 2 of the study explores giving the drug every day for 14 days. The study
uses healthy and psoriasis subjects.